Embecta Corp. (NASDAQ: EMBC) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $348M. The Maz Rating grades it against the other companies in its sector.
Embecta Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.15, Embecta Corp. trades at 4.1x trailing earnings and 0.3x sales, with an EV/EBITDA of 6.1. Over the last twelve months it generated about $1.0B of revenue and $86M of net income. It runs a gross margin of 59.9%, an operating margin of 24.8% and a net margin of 8.6%. It shows return on equity of -14.0%, return on invested capital of 17.8% and a free cash flow yield of 47.3%. On the balance sheet: a debt-to-equity ratio of -2.45 and a current ratio of 1.68. Over the past 52 weeks the share price ranged from $2.77 to $14.81, with a beta of 0.81.
Embecta Corp. pays a dividend yielding 5.28%, with 31% of earnings paid out. Its Maz Dividend Score is 1.90 out of 5, ranked against the other dividend payers in its sector (Safety 2.97, Growth 1.03, Yield 4.37, Consistency 1.85).
4 Wall Street analyst ratings cover the stock: 2 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.